What Aytu Biopharma, Inc does.

Aytu BioPharma, Inc. (“Aytu,” the “Company,” “we,” “us,” or “our”) is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. We were originally incorporated as Rosewind Corporation on August 9, 2002, in the state of Colorado and re-incorporated as Aytu BioScience, Inc. in the state of Delaware on June 8, 2015. In March 2021, we changed our name to Aytu BioPharma, Inc. Our common stock trades on the Nasdaq Capital Market LLC (the “Nasdaq”) under the ticker symbol “AYTU.” Our principal office is located at 7900 East Union Avenue, Suite 920, Denver, Colorado 80237, and our telephone number is (720) 437-6580.

Our strategy is to become a leading pharmaceutical company that improves the lives of patients. We use a focused approach of in-licensing, acquiring, developing and commercializing novel prescription therapeutics in order to continue building our portfolio of revenue-generating products and leveraging our commercial team’s expertise to launch and build leading brands within large therapeutic markets. In June 2025, we entered into an Exclusive Commercialization Agreement (the “Commercialization Agreement”) with Fabre-Kramer Holdings, Inc. (“Fabre-Kramer”) to commercialize EXXUA ("Gepirone") extended-release tablets (“EXXUA”) in the United States. Gepirone is a new chemical entity, and we believe EXXUA to be a novel first-in-class selective serotonin 5HT1a receptor agonist approved by the United States Food and Drug Administration (“FDA”) for the treatment of major depressive disorder (“MDD”) in adults. In fiscal 2026, we began selling EXXUA and made it the centerpiece of our commercial efforts.

Revenue and profit, by fiscal year.

More on AYTU.

• Aytu Biopharma, Inc summary
• Aytu Biopharma, Inc financial statements
• Aytu Biopharma, Inc key metrics
• Aytu Biopharma, Inc health scores and style box
• Aytu Biopharma, Inc earnings
• Aytu Biopharma, Inc dividends
• Aytu Biopharma, Inc valuation
• Aytu Biopharma, Inc ownership and insiders
• Aytu Biopharma, Inc peers

Figures from Aytu Biopharma, Inc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.